Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

UARK 99-006, A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia

NCT00083707 is registered in ClinicalTrials.gov with University of Arkansas as lead sponsor.

NCT NCT00083707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00083707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
UARK 99-006, A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia
Lead sponsor
University of Arkansas
Phase
Phase 2
Overall status
Completed
Start date
January 31, 1999
Completion date
February 28, 2003
Enrollment
40
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

waldenstrom macroglobulinemia